Administration of a,-adrenoblockers in the treatment of chronic prostatitis


Cite item

Full Text

Abstract

About the authors

B L Guschin

A G Martov

References

  1. Гринев А. В., Гвасалия Б. Р., Сердюцкий В. Е. Применение селективных альфа-блокаторов в комбинации с антибиотиками при хроническом простатите. Андрол. и генитал. хир. 2001; прил.: 117.
  2. Зелюнин П. Н., Князькин И. В., Сморчков А. А. и др. Дальфаз (альфузозин) в терапии больных хроническим простатитом. В кн.: Актуальные вопросы урологии и андрологии: Сборник научных трудов. СПб; 2001. 114-115.
  3. Камалов А. А. Современные взгляды на проблему хронического простатита. В кн.: Современные аспекты диагностики и лечения хронического простатита. Курск; 2000. 66- 71.
  4. Лямин Б. А. Диагностика и лечение хронического простатита. Там же. 85-90.
  5. Лереверзев А. С., Мысько С. Я., Россихин В. В. Особенности консервативного лечения аденомы предстательной железы в сочетании с хроническим простатитом. Там же. 116-117.
  6. Сегал А. С., Долгопятов Д. Г., Ахтаев Г. Г. Лечение простатодинии <х,-адреноблокаторами. Андрол. и генитал. хир. 2000; 1: 100.
  7. Сивков А. В., Толстова С. С., Егоров А. А., Ромих В. В. Роль комбинированного уродинамического исследования в диагностике нарушения мочеиспускания у пациентов с хроническим простатитом моложе 50 лет. В кн.: Современные аспекты диагностики и лечения хронического простатита. Курск; 2000. 145-146.
  8. Ткачук В. Н. Современные методы лечения больных хроническим простатитом: Пособие для врачей. СПб; 2000. 4-6.
  9. Толстова С. С. Роль уродинамических методов исследования в диагностике нарушения мочеиспускания при хроническом простатите. В кн.: Современные аспекты диагностики и лечения хронического простатита. Курск; 2000. 148-151.
  10. Awad S. A., Downie J. W. Sympathetic dyssynergia in the region of the external sphincter: a possible source of the lower urinary tract obstruction. J. Urol. (Baltimore) 1977; 118: 636-640.
  11. Barbalias G. A., Meares E. M., Sant G. R. Prostatodynia: clinical and urodynamic characteristics. Ibid. 1983; 130: 514-517.
  12. Barbalias G. A. Prostatodynia or painful male urethral syndrome? Urology 1990; 36: 146-153.
  13. Barbalias G. A., Nikiforidiw G., Liatsikos E. N. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J. Urol. (Baltimore) 1998; 159: 883-887.
  14. Barbalias G. A., Nikiforidis G., Liastikos E. N. Treatment of chronic prostatitis syndromes: evaluation of combining antibiotics and alpha-blockers. In: International prostatitis collaborative network: 2-nd Annual Meeting: Abstract book. Bethesda; 1999. 30.
  15. Blaylock N. J. Anatomical factors in prostatitis. Br. J. Urol. 1974; 46: 47-54.
  16. Brunner H., Weidner W., Schiefer H. G. Studies on the role of ureaplasma urealyticum and mycoplasma hominis in the prostatitis. J. Infect. Dis. 1983; 147: 807.
  17. Bushman W. Etiology of prostatitis. In: Lepor H., ed. Prostatic diseases. Philadelphia: W. B. Sounders Company; 2000. 550- 557.
  18. Caine M., Rax S., Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br. J. Urol. 1975; 47: 193-202.
  19. Caine M., Pfau A., Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Ibid. 1976; 48: 225.
  20. Chappie C. R. Pharmacotherapy for benign prostatic hyperplasia: the potential for a,-adrenoreceptor specific blockade. Ibid. 1998; 81 (suppl. 1): 34-47.
  21. De la Rossette J. J. M. С. H., Karthaus H. F. M., Kerrebroeck Ph. E. V. A. et al. Research in "prostatitis syndromes": the use of alfusosin (a new alpha-1 receptor blocking agent) in patients mainly presented with micturition complains of an irritative nature and confirmed urodynamic abnormalities. Eur. Urol. 1992; 22: 222-227.
  22. De la Rossette J. J. M. С. H., Hubregste M. R., Meuleman E. J. H. et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; 41: 301-302.
  23. Donker P. J., Ivanovichi F., Noach E. L. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br. J. Urol. 1972; 44: 180-193.
  24. Drabnick J. J., Mackey J. F., Gambel J. M. Prostatodynia in United Nations peace keeping force in Haiti. Mil. Med. 1997; 162: 380-383.
  25. Egan K. J., Krieger J. L. Chronic abacterial prostatitis: a urological chronic pain syndrome? Pain 1997; 69: 213-218.
  26. El Badawi A., Schenk E. A. A new theory of the innervation of the bladder musculature, IV innervation of the vesicourethral junction and external sphincter. J. Urol. (Baltimore) 1974; 111: 613.
  27. Foglar R., Shibata K., Hirasawa A. et al. Use of recombinant alpha-1 adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. 1995; 288: 201-207.
  28. Gushchin B. L., Martov A. G. Surgical (endourological) management in selected chronic prostatitis patients. In: International prostatitis collaborative network: 2-nd Annual Meeting. Abstract book. Bethesda; 1999. 38.
  29. Hellstrom W. J., Schmid R. A., Lue T. F. et al. Neumuscular dysfunction in nonbacterial prostatitis. Urology 1987; 30: 183- 188.
  30. Hieble J. P., Caine M., Zalaznik E. In vitro characterization of the alpha adrenoreceptors in the human prostate. Eur. J. Pharmacol. 1985; 107: 111-117.
  31. Hieble J. P., Bylund D. В., Clark D. E. et al. International Union of Pharmacology. X. Recommendations for nomenclature of alpha-1-adrenoreceptors: consensus update. Pharmacol. Rev. 1995; 47: 267-270.
  32. Hofmeister M. A., He F., Ratliff T. L. et al. Mast cells and nerve fibers in interstitial cystitis (1С): an algorithm for histologic diagnosis vai quantitative amage analysis and morphometry (QIAM). Urology 1997; 49 (suppl. 1): 41-47.
  33. Jardin A., Andersson K.-E., Chappie C. et al. a,-adrenoreceptor antagonists in the treatment of BPH. In: 5-th International consultation on BPH. Paris; 2000. 459-478.
  34. Kaplan S. А., Те A. E., Jackobs B. Z. Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic nonbacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J. Urol. (Baltimore) 1994; 152: 2063-2065.
  35. Kaplan S. A., Reis R. B. Significant correlation of the AUA symptom score and a novel urodynamic parameter: detrusor contraction duration. Ibid. 1996; 156: 1668.
  36. Kaplan S. A., Ikeguchi E. F., Santarosa R. P. et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996; 47: 836-839.
  37. Kaplan S. A., Santarosa R. P., D'Alisera P. M. et al. Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J. Urol. (Baltimore) 1997; 157: 2234-2237.
  38. Kawabe K. Current status of research on prostate-selective alphal-antagonists. Br. J. Urol. 1998; 81 (suppl. 1): 48-50.
  39. Kirby R. S., Lowe D., Bultitude M. I. et al. Intraprostatic urinary reflux: an aeteological factor in abacterial prostatitis. Ibid. 1982; 54: 729-731.
  40. Kohn I. J., Те А. Е., Kaplan S. A. The role of urodynamics in evaluating patients with chronic prostatitis. In: Nickel J. C, ed. Textbook of prostatitis. Oxford: ISIS Medical Media; 1999. 227-232.
  41. Krane R. J., Olsson С. A. Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturirion. J. Urol. (Baltimore) 1973; 110: 650-656.
  42. Lacquaniti S., Destito A., Servello С. et al. Terazosine and tamsulosin in nonbacterial prostatitis: a randomized placebo-controlled study. Arch. Ital. Urol. Androl. 1999; 71 (5): 283-285.
  43. Lepor H., Tang R., Meretyk S. et al. Alpha-1-adrenoreceptor subtypes in the human prostate. J. Urol. (Baltimore) 1993; 149: 640-642.
  44. Lepor H., Tang R., Shapiro E. The alpha-adrenoreceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301-307.
  45. Litwin M. S., McNaughton-Collins M., Fowler F. J. et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J. Urol. (Baltimore) 1999; 162: 369-375.
  46. Lowe F. С. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin. Ther. 1997; 19 (4): 730-742.
  47. McGrath J. C., Lepor H., Wyllie M. G. Report of a unique meeting between the alpha-blocker subcommittee and the pharmaceutical industry. Urology 1996; 48: 665-667.
  48. McNeal J. E. Regional morphology and pathology of the prostate. Am. J. Clin. Pathol. 1962; 49: 347-357.
  49. Meares E. M., Barbalias G. A. Clinical and video-urodynamic findings in prostatodynia. Semin. Urol. 1983; 1: 146.
  50. Moon T. D. Management of nonbacterial prostatitis and prostatodynia. In: Lepor H., ed. Prostatic diseases. Philadelphia: W. B. Sounders Company; 2000. 571-576.
  51. Naninnga J., Kaplan P., Lai S. Effect of phentolamine on periferal muscle EMG activity in paraplegia. Br. J. Urol. 1977; 49: 537.
  52. Narayan P. Benign prostatic hyperplasia. London: Churchill Livingstone; 2000. 155-170.
  53. National Kidney and Urologic Diseases Advirosy Board. Longrange plan window on the 21-st century. Bethesda: US Department of Health and Human Services; 1990.
  54. Neal D. E., Moon T. D. Use of terasosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994; 43: 460-465.
  55. Nickel J. С. Prostatitis: management strategies. Urol. Clin. N. Am. 1999; 26: 737-751.
  56. Nitti V. W., Combs A. J. Voiding dysfunction in young men. J. Urol. (Baltimore) 1997; 157: 188 (A730).
  57. Orland S. M., Hanno P. M., Wein A. J. Prostatitis, prostatosis and prostatodynia. Urology 1985; 25: 439-459.
  58. Osborn D. E., George N. G. R., Rao P. N. et al. Prostatodynia: physiological characteristics and rational management with muscular relaxants. Br. J. Urol. 1981; 53: 621-623.
  59. Roberts R. O., Lieber M. M., Bostwick D. G., Jakobsen C. J. A review of clinical and pathological prostatitis syndromes. Urology 1997; 49: 809-821.
  60. Ruffolo R., Nichols A., Stadel J. et al. Structure and function of alpha-adrenoreceptors. Pharmacol. Rev. 1991; 43: 475-505.
  61. Trockman B. A., Gerspach J., Dmochowski R. et al. Primary bladder neck obstruction: urodynamic findings and treatment results in 36 men. J. Urol. (Baltimore) 1996; 156: 1418-1420.
  62. Siroky M. В., Goldstein I., Kraine R. J. Functional voiding disorders in men. Ibid. 1980; 124: 200-204.
  63. Vaalasti A., Hervonen A. Autonomic innervation of the human prostate. Invest. Urol. 1980; 17: 293-297.
  64. Webster G. D., Lockhart J. L., Older R. A. The evaluation of bladder neck dysfunction. J. Urol. (Baltimore) 1980; 123: 196.
  65. Weiss S. G., Moon T. D. a-blocker therapy. In: Nickel J. C, ed. Textbook of prostatitis. Oxford: ISIS Medical Media; 1999. 319-327.
  66. Wheeler R. E., Selan R. G. The frequency of chronic prostatitis in 121 consecutive men with voiding symptoms. In: International prostatitis collaborative network: 2-nd Annual Meeting: Abstract book. Bethesda; 1999. 69.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies